Cargando…
In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease
Hemoglobin (Hb) released during hemolysis is a potent oxidant. Extracorpuscular Hb may enter the vessel wall and mediate low-density lipoprotein oxidation, thereby promoting the development and progression of atherosclerosis. Haptoglobin (Hp) is an antioxidant protein as a result of its ability to b...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993923/ https://www.ncbi.nlm.nih.gov/pubmed/17319095 |
_version_ | 1782135446997827584 |
---|---|
author | Asleh, Rabea Levy, Andrew P |
author_facet | Asleh, Rabea Levy, Andrew P |
author_sort | Asleh, Rabea |
collection | PubMed |
description | Hemoglobin (Hb) released during hemolysis is a potent oxidant. Extracorpuscular Hb may enter the vessel wall and mediate low-density lipoprotein oxidation, thereby promoting the development and progression of atherosclerosis. Haptoglobin (Hp) is an antioxidant protein as a result of its ability to bind Hb and block Hb-induced oxidative damage. Hp also facilitates the removal of Hb from the extravascular compartment via the CD163 macrophage scavenger receptor. In man, there are two common alleles for Hp denoted 1 and 2, and correspondingly, three different possible genotypes: Hp1-1, Hp2-1, and Hp2-2. We have recently demonstrated in several longitudinal studies that Hp genotype is an independent risk factor for diabetic vascular complications. Specifically, we have shown that diabetic individuals with Hp 2-2 are more likely to develop nephropathy, retinopathy, and cardiovascular disease as compared with those with Hp2-1 or Hp1-1. Mechanistically, we have found significant Hp type differences in the antioxidant and CD163-mediated scavenging and activation functions of the different Hp protein types. Furthermore, we have demonstrated that these functions are modified in the diabetic state. In this review, we focus on the clinical studies associating the Hp polymorphism and diabetic vascular complications, and the molecular basis behind this interaction. |
format | Text |
id | pubmed-1993923 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2005 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-19939232008-03-06 In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease Asleh, Rabea Levy, Andrew P Vasc Health Risk Manag Review Hemoglobin (Hb) released during hemolysis is a potent oxidant. Extracorpuscular Hb may enter the vessel wall and mediate low-density lipoprotein oxidation, thereby promoting the development and progression of atherosclerosis. Haptoglobin (Hp) is an antioxidant protein as a result of its ability to bind Hb and block Hb-induced oxidative damage. Hp also facilitates the removal of Hb from the extravascular compartment via the CD163 macrophage scavenger receptor. In man, there are two common alleles for Hp denoted 1 and 2, and correspondingly, three different possible genotypes: Hp1-1, Hp2-1, and Hp2-2. We have recently demonstrated in several longitudinal studies that Hp genotype is an independent risk factor for diabetic vascular complications. Specifically, we have shown that diabetic individuals with Hp 2-2 are more likely to develop nephropathy, retinopathy, and cardiovascular disease as compared with those with Hp2-1 or Hp1-1. Mechanistically, we have found significant Hp type differences in the antioxidant and CD163-mediated scavenging and activation functions of the different Hp protein types. Furthermore, we have demonstrated that these functions are modified in the diabetic state. In this review, we focus on the clinical studies associating the Hp polymorphism and diabetic vascular complications, and the molecular basis behind this interaction. Dove Medical Press 2005-03 /pmc/articles/PMC1993923/ /pubmed/17319095 Text en © 2005 Dove Medical Press Limited. All rights reserved |
spellingShingle | Review Asleh, Rabea Levy, Andrew P In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease |
title | In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease |
title_full | In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease |
title_fullStr | In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease |
title_full_unstemmed | In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease |
title_short | In Vivo and In Vitro Studies Establishing Haptoglobin as a Major Susceptibility Gene for Diabetic Vascular Disease |
title_sort | in vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993923/ https://www.ncbi.nlm.nih.gov/pubmed/17319095 |
work_keys_str_mv | AT aslehrabea invivoandinvitrostudiesestablishinghaptoglobinasamajorsusceptibilitygenefordiabeticvasculardisease AT levyandrewp invivoandinvitrostudiesestablishinghaptoglobinasamajorsusceptibilitygenefordiabeticvasculardisease |